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ABSTRACT OF THE DISSERTATION

Radiolabeled nanohydroxyapatite as a platform for the development of new PET imaging agents
by
Stacy L. Queern
Doctor of Philosophy in Chemistry
Washington University in St. Louis, 2018
Dr. Suzanne E. Lapi, Co-Chair
Dr. Kevin Moeller, Co-Chair
Positron emission tomography (PET) imaging utilizes drugs labeled with positron emitters to
target and evaluate different biological processes occurring in the body. Tailoring medicine to
the individual allows for higher quality of care with better diagnosis and treatment and is a key
purpose for advancing research into developing new platforms for PET imaging agents. A PET
nuclide of high interest for the development of these agents is 89Zr. This can be attributed to the
long half-life of 3.27 days and low positron energy of 89Zr.
In this work, we developed a production method for

89Zr

using Y sputtered coins that is now in

current use at the University of Alabama at Birmingham for both research and human-use
studies. An alternative means of separation for

89Zr

from Y using IDA as an eluant with

inorganic resin obtained from Brookhaven National Laboratory was also investigated in order to
develop a method that alleviated the necessity to remove the chelator before human injections.
The low-level activity separations were reproducible with successful test labeling showing the
potential this method has as an alternative separation method.
viii

Although

89 Zr

has great potential as PET nuclide, it is a known bone seeker, meaning if it

decomplexes from a chelator, it will be taken up in the bone. The natural affinity of 89Zr for bone
can be exploited as a radiolabeling technique using nHAp. Nanoparticles composed of the main
component in the bone matrix, nHAp, were used to exploit the natural affinity of 89Zr and other
bone-seekers have for bone to develop a platform for PET imaging agents. The particles were
easily labeled with high stability and little bone uptake in vivo. As a proof of concept that this
could be used to develop targeted imaging agents, co-precipitated nHAp was rapidly modified
with an analog of TOC to target SSTR2 receptors in AR42J cells to show specific targeting. Both
the cells studies and the preliminary animal studies showed that there was specific targeting of
the novel agents. Overall, the preliminary studies with

89Zr-nHAp-phospha-TOC

promising for nHAp as a new platform for PET imaging agents.

ix
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Chapter 1
Introduction
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1.1 Nuclear Chemistry
There are several types of radioactive decay, which essentially result in a loss of energy from the
nucleus of an atom. The important decay pathways for this work include beta decay and gamma
decay. The nuclear equations and a schematic for each type of decay are shown in Figure 1-1.
Beta decay consists of three different modes: negative electron emission (β -), positron emission
(β+), and electron capture (ε). In beta decay, the emitted particle energies have a continuous
distribution with a maximum energy of Emax where Emax is the difference in the initial and final
energies of the nuclear state with a subtraction due to the small recoil correction from the
daughter nuclide [1-2]. For all nuclear reactions, the change in energy between the initial and
final states is referred to as the Q-value.
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Figure 1-1 Radioactive decay modes

Nuclides that are neutron rich will have a high probability of undergoing β - decay. In β- decay,
the nucleus of a neutron rich nuclide emits an antineutrino (𝜈̅ ) and an electron. This can be
thought of as converting a neutron into a proton and increases the value of the atomic number (Z)
by one while decreasing the number of neutrons (N) by one. This results in the overall mass
number (A) remaining the same [1-2]. Generally, nuclides that undergo β- decay with half-lives
amenable to clinical use can be used to develop radiotherapeutics to help treat disease [3-5]. A
relevant medical isotope that undergoes β- decay is 153Sm with a half-life of 46.5 hours [6].
Nuclides that are proton rich may undergo β+ or ε decay. In β+ decay, the nucleus emits a
neutrino (𝜈) and a positron, effectively converting a proton into a neutron. The ejected positron
3

will annihilate with an electron emitting two photons in opposite directions (approximately 180 ᴼ)
to each other. This type of decay occurs more frequently with lighter nuclei and requires a
difference in a mass of the parent and daughter (or Q-value) of greater than 1.02 MeV, the mass
of two electrons. For heavier nuclei and for nuclides with a Q-value lower than 1.02 MeV, ε
decay is a more probable route of decay. During electron capture, the nucleus captures an
orbiting electron effectively converting a proton into a neutron. During ε, there are emissions of
x-rays and/or Auger electrons. Auger electrons are low energy electrons emitted from the outer
shells of an atom. In both β+ and ε decay, the value of Z decreases by one while N increases by
one to maintain a constant A for the parent and daughter nuclide [1-2]. A parent nuclide may
decay by multiple routes (each with a different probability) when there is more than one route
available. This is known branching decay. Branching decay of β+ and ε decay is seen in the
decay of 55Co where β+ decay occurs 77% of the time while ε decay occurs 23% of the time [79].
Nuclides that experience beta decay can result in a daughter nuclide in an excited (or metastable)
state. This daughter nuclide emits photons or electrons to deexcite to ground state. This decay is
known as gamma decay or internal conversion, respectively. An example of this decay is the
decay from

89mZr

to

89gZr. 89mZr

has a half-life of 4.16 minutes with a 94% branching ratio for

internal conversion. An example of a decay scheme for 89mZr to 89gZr and 89Y is shown Figure 12 [7].
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Figure 1-2 Decay scheme for 89mZr

There are several methods to produce radionuclides for research or clinical activities. In this
work, the majority of the radionuclides used were produced using a cyclotron. A cyclotron is a
particle accelerator that accelerates charged particles such as protons in a circular path. The ion
source releases ions in between two electrodes, often referred to as “dees” for their shape
historically. The two dees, where the particles travel, are hollow and shield them from the
electric field. Once the particle exits one dee, there is a gap the particle crosses to enter the
second dee. In this gap, the electric field will act on the particle accelerating it across and into the
opposite dee. To constrain the particles to circular path, the dees are located in a static magnetic
field perpendicular to the electric field [1, 8, 10]. As the particles accelerate, the radius of the
5

path increases until they reach a desired radius/energy. For negative ion accelerators, the
extraction port provides a change to the path of negative particles by using extraction foil to strip
off electrons. The loss of electrons changes the charge of the ions allowing them to exit the
cyclotron into the target material to induce a nuclear reaction [8]. A schematic of a cyclotron is
given in Figure 1-3 [1, 8].

Figure 1-3 Cyclotron schematic

For the production of radionuclides in this work, the main nuclear reactions occur when the
nucleus of the target material gains a proton and releases a neutron or alpha particle to obtain the
radionuclide of interest. The relevant isotopes are listed in the Table 1-1 [5, 7, 9, 11].
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Table 1-1 Relevant radionuclides, production routes, and decay characteristics

Radionuclide

Half-life (h)

Production Route

Decay Routes

Eβ+max (keV)

β+ (23%)
89Zr

78.41

89Y(p,n)89Zr

ε (77%)

897

β+ (96.7%)
18F

1.83

18O(p,n)18F

153Sm

46.5

152Sm(n,γ)153Sm

64Cu

12.7

64Ni(p,n)64Cu

ε (3.3%)
β- (100%)

805 (β-)

β+ (17.6%)

653

ε (43.9%)
β- (38.5%)

55Co

17.53

58Ni(p,α)55Co

635

579 (β-)

β+ (77%)
ε (23%)

1500

The energy of the accelerated particle plays a significant role in the production of these nuclides.
A minimum threshold energy is required to induce a nuclear reaction and produce any
radionuclide [1, 10]. Once the threshold energy is overcome, the probability of the reaction
occurring (cross-section) may be considered [2, 10]. The cross-section plotted against the energy
of the projectile is called an excitation function [10, 12]. The excitation function helps determine
the range of energies optimal for the production of the radionuclide of interest. An example of an
excitation function for the 89Y(p,n)89Zr reaction is shown in Figure 1-4 [7, 13].
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Figure 1-4 Experimental excitation function for 89Y(p,n)89Zr [7, 13]

1.2 Nuclear Medicine
The use of small amounts of radioactivity for diagnosis and treatment of disease is collectively
referred to as nuclear medicine. One major tool in nuclear medicine is positron emission
tomography (PET) imaging. PET imaging is a noninvasive and quantitative imaging technique
that allows for research, diagnosis of disease and development of effective treatment plans.
PET is based on the principle that once a PET nuclide is administered, the nucleus emits a
positron and approximately 1 - 10 mm from the emission site, this positron annihilates with an
electron to produce two 511 keV photons moving in essentially opposite directions [10]. These
photons are detected in coincidence at 180o using scintillation detectors that surround the subject
(see Figure 1-5). The images are then reconstructed using each event that is detected in
coincidence. One key factor in the resolution of a PET image is the energy of the emitted
positron. The maximum positron energy, Eβ+max, is a limiting factor for image resolution because

8

higher energy positrons will propagate through tissue much further then lower energy positrons
before the annihilation event occurs [12].

Figure 1-5 PET scanner schematic

The most commonly used PET nuclide is

18F

which has an Eβ+max of 635 keV and a half-life of

109.8 minutes [14-15]. Additionally, there are many other PET nuclides currently in use. Table
1-1 shows the common PET nuclides found in this work and their characteristics.
When PET nuclides are utilized in compounds, they are known as PET tracers or
radiopharmaceuticals. Most of the time PET tracers are PET nuclides tethered to a targeting
agent that delivers the PET nuclide to the intended area (see Figure 1-6). Ideal candidates for
PET nuclides would have low Eβ+max and a half-life that matches the biological half-life of agent
being studied. All PET tracers should have a relatively short half-life to minimize the radiation
exposure to the subject, they should be easily modified and stable, and have a high specific
9

activity. Specific activity is a measure of radioactivity per total mass and is generally expressed
as the amount of radioactivity per mole of compound [1, 8, 12]. Compounds with high specific
activity allow for less mass to be used in the dose administered to the patient. This is particularly
important when targeting receptors in low abundance or when using pharmacologically active
compounds as imaging agents. While there are currently several PET tracers used clinically, the
most commonly used PET tracer is 2-[18F]fluoro-2-deoxyglucose ([18F]FDG) which is used for
measuring metabolic activity for diagnosis of cancer and other disease states [8, 16-17].
Occasionally, PET nuclides can be injected without being tethered to a targeting agent when the
nuclide has a natural high affinity for the intended area. For example,

18F

(as F-) has a natural

affinity for bone and is used in bone imaging studies [18-19]. There are a few radionuclides that
are bone-seekers with a naturally high affinity for bone, such as 89Zr, 18F, and 153Sm.

Figure 1-6 PET tracers and targeting mechanisms

10

The development of PET tracers utilizing 89Zr has been of high interest due to its half-life of 3.27
days [20-21]. This long half-life relative to

18F

(109.77 min) is compatible with the biological

half-life of antibodies providing longer imaging time points for PET [20, 22-23]. The β+
branching ratio for 89Zr is 23% and offers high resolution images and quantitative imaging with a
maximum positron energy of 0.897 MeV [21-22]. Although

89Zr

has great potential as PET

nuclide, it is a known bone seeker [23-24]. Thus, if the 89Zr complex is not stable in vivo and the
89Zr

decomplexes, it’s affinity to bone may cause unnecessary dose for the patient.

In this work, methods for production of

89Zr

using both organic and inorganic resins for

purification were developed and are discussed in chapters 2 and 3, respectively. Chapter 4
investigates the radiolabeling of nanohydroxyapatite (nHAp), the main component in bone
matrix, as a new platform for PET imaging agents. Both known bone-seekers,
153Sm,

and non-bone-seekers,

64Cu

and

55Co,

89Zr, 18F

and

were investigated to compare the labeling and

stability of radiolabeled nHAp. Two different morphologies of nHAp, sphere and needle, were
compared to determine the impact of the shape on the biological properties. Chapter 5 covers an
alternative co-precipitation method of nHAp, radiolabeling and modification with the peptide
based phosopha-TOC to target SSTR2 receptors which are overexpressed on neuroendocrine
tumors. These particles were employed in cell studies using the AR42J cell line to show specific
targeting. Rat pancreatic tumors were implanted in immunodeficient mice to assess the in vivo
targeting properties of

89Zr-nHAp-phospha-TOC.

In chapter 6, conclusions and thoughts for

future work are provided. Overall, the goal of this work was to implement nHAp as a new
platform for PET imaging agents using 89Zr-nHAp-phospha-TOC as a proof of concept.
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Chapter 2
Production of 89Zr using sputtered yttrium
coin targets
[This work has been published previously as “Production of 89Zr using sputtered yttrium coin
targets,” Stacy L Queern, Tolulope A. Aweda, Adriana V. F. Massicano, Nicholas A. Clanton,
Retta El Sayed, Jayden A. Sader, Alexander Zyuzin, and Suzanne E. Lapi, Nuclear Medicine and
Biology. 2017, 50, 11-16]
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2.1 Introduction
Radionuclides for radiotracers used in medical imaging can be produced on an accelerator or in a
nuclear reactor. A cyclotron is a type of accelerator which offers many advantages for the
production of these radionuclides. A medical cyclotron is generally smaller than a linear
accelerator, making it more feasible to have on sites with size constraints such as hospitals and
universities. Furthermore, the use of a proton accelerating cyclotron (as opposed to a reactor)
typically provides products of a different element than the initial target material, allowing for
chemical separations leading to a product with high specific activity. Cyclotrons also allow for
the production of radionuclides with low impurities through selection of the proper target
material and energy range for the protons used in the nuclear reaction. Regarding the production
of the radionuclides using a cyclotron, there are two properties of the beam that need to be taken
into consideration. The energy of the protons needs to be high enough for the nuclear reaction to
occur while remaining in the range of energies to minimize the amount of impurities being
produced where possible. Additionally, the beam current will impact the amount of activity
being produced. The current needs to be high enough to provide suitable amounts of
radioactivity without significantly damaging the target material due to the heat deposited from
the beam.
There has been an increasing interest in the production of

89

Zr, mainly due to the 89Zr half-life

which is compatible with antibody imaging [1-4]. Additional characteristics of this isotope
include the ability to carry out high resolution and quantitative imaging due to the branching
ratio for β+ emission (23%) and low average positron energy (396 keV) [1, 3, 5]. While 89Zr also
emits a γ-ray at 909 keV at a branching ratio of 99% which is suboptimal for dosimetry, the
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longer half-life of

89 Zr

(3.27 days) relative to the short half-life of commonly used

18F

(1.83

hours) has propelled its demand in nuclear medicine for positron emission tomography (PET) for
the development of imaging agents requiring longer imaging time points [5-7].
The current method of production for

89Zr

is typically via cyclotron or linear accelerator using

natural abundance yttrium via the 89Y(p,n)89Zr reaction. Several different types of target material
have been investigated including yttrium foil, yttrium oxide powder, yttrium sputtered onto
copper, electrodeposition of yttrium, and aqueous yttrium nitrate [1, 3, 8-11]. While there are
several reports investigating and optimizing foil, powder and solution targets, there are few
reports using sputtered yttrium.
By examining the cross-sections for the production of

89Zr

and

88Zr,

theoretical calculations of

activity and beam energy optimization can be determined [12-13]. Figure 2-1 shows the
production of 89Zr via the 89Y(p,n)89Zr reaction is optimal at low proton beam energy (<13 MeV)
while at higher beam energy, 88Zr as a contaminant is introduced via the

89Y(p,2n)88Zr

reaction

[14-15]. While the co-production of 89Zr and 88Zr is inevitable at higher energies, the production
of 88Zr can be eliminated by using a lower proton beam energy of <13 MeV [7].
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Figure 2-1 Cross-section comparison of 89Y(p,n)89Zr and 89Y(p,2n)88Zr [14-15]

While several

89 Zr

purification methods have been reported, including solvent exchange, anion

exchange, or hydroxamate resin, most groups typically use the latter [1, 3, 5-6, 8, 16-17]. Several
groups have standardized the method using the hydroxamate resin allowing for >99.5% activity
recovery [1, 3-4].
Our goal was to optimize the beam energy from the UAB TR-24 cyclotron using aluminium
degraders to minimize the production of
production of

89Zr.

88Zr,

and determine the optimal conditions for the

Typically using less target mass allows for more efficient separation, high

specific activity and lower contaminants, therefore yttrium sputtered coins were assessed as a
target material hypothesizing that the sputtered coins would allow for more control over the
target cross sectional area and total mass of yttrium. In this work, we investigated the
bombardment of solid yttrium coins and yttrium sputtered target coins as production methods for
89

Zr.
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2.2 Material and Methods
Aluminum Degrader and Yttrium coins: Aluminum degrader coins were manufactured at the
UAB machine shop using 6061 aluminum alloy. The aluminum discs were machined in 0.5 mm,
0.75 mm and 1 mm thickness. Yttrium sheets with a thickness of 1 mm (ESPI metal, Ashland,
Oregon) and cut to specified coin size to allow for irradiation in the coin target holder (ACSI,
Richmond, Canada). Examples of these coins can be seen in Figure 2-2.

Figure 2-2 6061 Aluminum alloy degrader (left) Yttrium coin (right)

Yttrium (99.9%) sputtered niobium (99.8%) coins, supplied by Advanced Cyclotron Systems,
Inc. (ACSI), were investigated as an alternative method of production. The niobium coins had a
diameter of 24 mm and a thickness of 1 mm and were cleaned with organic solvent to remove
machine oil and lightly sanded. The yttrium was adhered to the coin via magnetron sputtering,
vapor deposition, using a mask in the center of the niobium coin with a diameter of 10 mm to
contain the sputtering with thickness ranging from 90 μm to 250 μm (Figure 2-3).
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Figure 2-3 Top Left: Cyclotron Coin target holder; Top Right: Disk Assembly; Bottom: Sputtered Coins: Coin 1
(left) 110 µm; Coin 2 (middle) 140 µm; Coin 3 (right) 90 µm

Simulations and Calculations: Transport of Ions in Matter (TRIM) was used to calculate the exit
beam energy through the aluminum degrader. This exit energy was used in the theoretical
activity yield calculations for the 89Y(p,n)89Zr and

89Y(p,2n)88Zr

(if applicable) using the NNDC

website to obtain cross-sections [18] and Stopping and Range of Ions in Matter (SRIM) software
[19] to find the correlating range for each energy. This was repeated for several different beam
energies and degrader thicknesses.
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The theoretical predicted activity was calculated using thin target estimation [20].
𝐴 = 𝜑𝑥𝜎𝑁𝑡𝑔𝑡 𝑡𝜆.

(1)

where ϕ is the flux of the proton beam, A is the activity of the isotope produced (Bq), x is range
in the material (cm), σ is the cross section (cm2), Ntgt is the density of the target nuclei
(atoms/cm3), t is the duration of bombardment (s), and λ is the decay constant (s -1).
Optimizing Cyclotron Conditions: Various irradiations of the target using yttrium coins were
performed. The beam energy was varied in 100 keV increments until the beam profile provided
maximum transmission. The sputtered coins were bombarded for 30 minutes with a 12.5 MeV
degraded beam energy using a 0.75 mm aluminum degrader (initial proton energy 17.5 MeV) or
two hours with a 12.8 MeV degraded beam energy using a 0.75 mm aluminum degrader (initial
proton energy 17.8 MeV) and current was increased for each subsequent coin.
89Zr

Radiopurity Analysis: The yttrium coins or yttrium sputtered layers were dissolved in 2 M

HCl and an aliquot was removed for gamma spectroscopy analysis using a high purity
germanium detector (Ortec, Oak Ridge, Tennessee). The amount of

89Zr

and any additional

radiocontaminants present in the sample were determined.
Separation and Purification: Conditions for the

89 Zr

purification are given in Table 2-1 with the

average elution volume for recovery of g 89Zr. The irradiated yttrium coins were dissolved in 50
mL of 2 M HCl at 80ᴼC [1]. The entire dissolution process for the coins took about 2 h.
Hydroxamate resin was prepared by functionalizing a weak cation exchange resin with
hydroxamate groups as previously reported [3]. A column was packed with 850 mg of the
hydroxamate resin and loaded with the dissolved yttrium target. Using 2 X 40 mL of 2 M HCl,
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the yttrium was eluted from the column followed by 40 mL of water to rinse the HCl off the
column. Elution of 89Zr was achieved with a range between of 3 - 14 mL of 1 M oxalic acid.
Complete dissolution of the yttrium layer from the sputtered coin was achieved with 4 mL of 2
M HCl at 80ᴼC in 20 minutes. Yttrium was eluted from a 100 mg of hydroxamate resin column
with 2 X 10 mL of 2 M HCl followed with 10 mL of water to wash the column, and

89 Zr

was

eluted with 1 - 1.5 mL of 1 M oxalic acid.
Table 2-1 Separation Parameters

Yttrium Coins

Sputtered Coins

Original Mass of Yttrium

2g

20-60 mg

Dissolution Time

2h

15-30 min

Hydroxamate Resin Mass

850-900 mg

100 mg

Yttrium Elution

80 mL

20 mL

Zr-89 Elution (1 M Oxalic
Acid)

7.3 mL

1.2 mL

Specific Activity Analysis and Radiolabeling: DFO-SCN was dissolved in DMSO to make a
stock solution and serial dilutions were prepared using 1 M HEPES buffer as the diluent. 20 μCi
of the prepared 89Zr were added to each dilution and DTPA was used to challenge the solution.
The resulting solutions were analyzed using TLC to determine the effective specific activity [1,
3, 21]. Solutions were also obtained from several samples prior to and after the purification
process. These solutions were analyzed by ICP-MS (Agilent, Santa Clara, California) and the
amount of yttrium, zirconium, aluminum, niobium, and iron in each sample was measured. To
examine the utility of the purified

89Zr,

a typical antibody labeling was conducted [2, 21-23].

DFO-Trastuzumab and 89Zr were combined to give a specific activity of 8 μCi/μg. The solution
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was incubated at 37ᴼC with agitation for one hour. The solution was challenged with 50 mM
DTPA for 5 minutes. Results were then analyzed using ITLC plates with 50 mM DTPA as the
mobile phase on TLC scanner (Eckert & Ziegler, Berlin, Germany).

2.3 Results
Simulations and Calculations: The simulation for 17.8 MeV beam energy propagating through a
0.75 mm aluminum degrader, and the projected path of a 17.8 MeV beam through a 0.75 mm
aluminum degrader and 1 mm yttrium coin can be seen in Figure 2-4. These simulations show
the range of the beam in the material and the deviation of the beam from the center. This
illustrates that the beam will not propagate through the entirety of the material and no
contamination of the water cooling system will occur.

Figure 2-4 Projected path of the proton beam through matter. 0.75 mm Aluminum (left), 0.75 mm Aluminum and 1
mm Yttrium (right) [19]
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A simulation for the sputtered coins with a 17.8 MeV proton beam energy and a 0.75 mm
aluminum degrader was also conducted. The energy exiting the aluminum degrader was
calculated to be 12.8 MeV and the exiting energy for the yttrium layer was 10.9 MeV. Although
this energy may activate the niobium backing of the sputtered coins, there are several advantages
to using niobium. Niobium is chemically inert, affordable and provides a reliable sputtering
support material for yttrium.

Figure 2-5 TRIM simulation for the sputtered Coin [19]
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Figure 2-5 shows that the beam propagates through all three materials and stops in the niobium
backing. The following table (Table 2-2) shows the results obtained from performing the Monte
Carlo simulations for the energy degradation through the aluminum coin and the theoretical
activity of

89Zr

and

88Zr

(if applicable). The calculated energy threshold for

88 Zr

production is

13.08 MeV, which can be considered the upper limit on the beam energy for the production of
89Zr.
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Table 2-2 89Zr Production using a current of 10 µA and irradiation time of 20 minutes

Beam
Energy
(MeV)

Aluminum
Thickness
(mm)

Transmitted
Energy
(MeV)

16

0.5

12.5

3.75

NA

16.5

0.5

13.1

4.41

NA

16.5

0.75

11.1

2.51

NA

16.5

1

8.86

0.57

NA

16.7

0.5

12.5

3.75

NA

17

0.5

13.7

5.03

0.05

17

0.75

11.8

3.11

NA

17

1

9.65

0.98

NA

17.5

0.5

14.3

6.18

1.11

17.5

0.75

12.5

3.75

NA

17.5

1

10.4

1.46

NA

17.8

0.75

12.8

3.93

NA

18

0.5

14.9

6.73

3.99

Calculated Threshold Energy for Zr-88
using Q-value and Coulomb Barrier

Predicted
Predicted
Activity Zr-89 Activity Zr-88
(mCi)
(µCi)

13.08 MeV

Optimizing Cyclotron Conditions: The lowest beam energy for an optimal profile and
transmission was determined through iterations of the ion source and magnet system settings on
the cyclotron. The lowest effective beam energy of 17 MeV gave a transmission of 81%. The
best theoretical energy for the production of 89Zr using the aluminum degrader would be at 17.8
MeV using a 0.75 mm thick aluminum degrader.
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The theoretical calculations and activity of each coin after bombardment are given in Table 2-3.
Although there are four yttrium coins listed in Table 2-3, six irradiation attempts were made for
each type of coin. Two of the yttrium coins were damaged during a 2 h irradiation using 17.8
MeV beam energy as can be seen in Figure 2-6.

Figure 2-6 Damage to the yttrium coins (Y 5, Y 6) with 2 h irradiation with 12.8 MeV transmitted beam energy
(17.8 MeV initial beam energy) and 40 µA current.

The following figure (Figure 2-7) shows the sputtered coins after various irradiation conditions.
The physical appearance of the coins clearly shows an increase in scorching as the current and
duration of irradiation increases.

26

Figure 2-7 (from left to right) Sputtered Coin 1 t=30 min, 10 μA, 12.5 MeV; Sputtered Coin 2 t=30 min, 21 μA, 12.5
MeV; Sputtered Coin 3 t=30 min, 30 μA, 12.5 MeV; Sputtered Coin 6 t=2 h, 40 µA, 12.8 MeV; Sputtered Coin 5
t=2 h, 45 µA, 12.8 MeV

Radiopurity Analysis: The following table (Table 2-3) provides a summary of the radionuclides
found in the analysis of the coin targets.
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Table 2-3 Activity measured on HPGe for irradiated targets

Coin

Y1

Y2

Y3

Yttrium
Thickness
1 mm

1 mm

1 mm

Isotope

AMeasured
of Coin

ATheoretical

89Zr

5.13 mCi

4.71 mCi

88Zr

13.6 μCi

3.99 μCi

89Zr

3.15 mCi

3.18 mCi

88Zr

Not
Observed

NA

89Zr

8.08 mCi

10.06 mCi

88Zr

8.57 μCi

0.05 μCi

89

66.24 mCi

89.26 mCi

88Zr

Not
Observed

NA

89Zr

1.63 mCi

1.82 mCi

88Zr

Not
Observed

----

89Zr

3.94 mCi

4.86 mCi

88Zr

Not
Observed

----

89Zr

2.60 mCi

4.46 mCi

88Zr

Not
Observed

----

89Zr

25.37 mCi

31.28 mCi

88Zr

Not
Observed

----

89Zr

43.8 mCi

45.27 mCi

88Zr

Not
Observed

----

89Zr

21.9 mCi

23.09 mCi

88Zr

Not
Observed

----

Zr

Y4

Sputtered
Coin 1

Sputtered
Coin 2

Sputtered
Coin 3

Sputtered
Coin 4

Sputtered
Coin 5

Sputtered
Coin 6

1 mm

110 μm

140 μm

90 μm

220 μm

210 μm

90 μm
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Transmitted
Energy

Current

Time

14.9 MeV

7 μA

20 min

12.5 MeV

8.5 μA

20 min

13.7 MeV

20 μA

20 min

12.8 MeV

40 μA

2h

12.5 MeV

10 μA

30 min

12.5 MeV

21 μA

30 min

12.5 MeV

30 μA

30 min

12.5 MeV

40 μA

2h

12.8 MeV

45 μA

2h

12.8 MeV

40 μA

2h

The first yttrium coin was irradiated with an initial beam energy of 18 MeV degraded to 14.9
MeV. As these conditions resulted in significant amounts of 88Zr, the target was not dissolved for
analysis. The coin, however, was analyzed for 88Zr once the 89Zr had decayed.
Table 2-3 shows that

88Zr

is still present with the beam energy only degraded to 13.7 MeV. In

order to obtain minimal 88Zr with maximum 89Zr, an incident beam energy of 17.5 MeV or 17.8
MeV was used in subsequent irradiations with a 0.75 mm aluminum degrader to give a
transmitted beam energy of 12.5 MeV or 12.8 MeV, respectively. This is verified in the sputtered
coin targets.
Separation and Purification: Following purification of the irradiated yttrium coins, 88.3 ± 4.9%
of the loaded

89Zr

was recovered in an average of 7.3 mL of 1 M oxalic acid. Following

purification of the sputtered coins 97.9 ± 2.8% of the loaded

89 Zr

was obtained in an average of

1.2 mL of 1 M oxalic acid as shown in Table 2-4. In Table 2-4, ALoaded represents the activity that
was recovered after dissolution and loaded onto the column, Volume represents the recovery
volume for the bulk activity elution (AEluted), and the Total Yield, % represents the total activity
recovered overall.
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Table 2-4 Purification yield of 89Zr

Coin

ALoaded on
Column
(mCi)

Bulk
Collection
Volume
(mL)

Total
Volume
(mL)

Bulk
AEluted
(mCi)

Y1
Y2

8.3

12

Not Purified
14
5.5

Y3
Y4

3.3
53.4

2
3

3
5

Sputtered
Coin 1 (1)

2.6
47.8

Elution
Yield, %

Total
Yield, %

66.3

92.1

78.8
88.6

82.8
89.9

Not Purified

Sputtered
Coin 2 (2)

2

1

1.25

1.9

95

99.5

Sputtered
Coin 3 (3)

2

1

1.25

1.8

90

96

Sputtered
Coin 4
(9A)

25.3

0.5

1

21.3

84.2

93.8

Sputtered
Coin 5
(4A)

33.9

1

1.5

33.8

99.7

100

Sputtered
Coin 6
(1A)

12.8

0.5

1

11.1

86.7

100

89Zr

Analysis: The

89Zr

effective specific activity was determined using DFO titration with

values of 20.3 mCi/µmol for the solid yttrium coin productions and 108 ± 7 mCi/μmol for the
yttrium sputtered coin productions. The ICP-MS analysis of the yttrium coin and the sputtered
coins showed 99.99% yttrium removed with 178 μg of yttrium in the final solution and 99.93 100% of yttrium was removed with 0 - 42 μg of yttrium in the final solution, respectively. ICP30

MS analysis was used to determine the concentration of other impurities present in the solution,
such as zirconium, aluminum and iron. Niobium for all samples were below the detection limits
of the instrument. Table 2-5 provides the concentrations found each element in the solutions. The
specific activity calculated for the Y 4 coin and the sputtered coins 2, 3 and 4 using the
concentration of Zr found via ICP-MS was 140 ± 2 mCi/μmol, 300 ± 30 mCi/μmol, 410 ± 60
mCi/μmol and 1719 ± 5 mCi/μmol, respectively. DFO-Trastuzumab was successfully labeled
with 89Zr produced from the sputtered yttrium coins with yields between 98% - 100%.
Table 2-5 ICP-MS analysis of yttrium coin and the sputtered coin

Sample
Yttrium
Coin

Y-89 (ppb)

Zr-90 (ppb)

Al-27 (ppb)

Fe-56 (ppb)

Crude

3.381(±0.017)x107

3.8(±0.4)x104

10(±0.2)x106

7.6(±0.3)x105

Purified

3.02(±0.08)x103

1.039(±0.015)x104

5(±3)x102

5.4(±0.2)x102

Crude

7.58(±0.03)x106

6.5(±0.5)x103

9(±4)x104

7.35(±0.16)x104

5.47(±0.09)x103

5.9(±0.6)x102

6.2(±0.3)x103

7.1(±0.4)x103

4.49(±0.05)x106

4.5(±0.4)x103

4(±3)x104

7.2(±0.9)x104

6.3(±0.5)x102

4.0(±0.6)x102

2.1(±0.9)x104

3.29(±0.09)x104

1.639(±0.014)x107

2.23(±0.08)x103

9.9(±1.9)x103

8.07(±0.16)x103

5.36(±0.19)x102

2.261(±0.006)x103

9(±3)x102

9.0(±0.3)x102

Sputtered
Coin 2
Purified
Crude

Sputtered
Coin 3
Purified
Crude

Sputtered
Coin 4
Purified

2.4 Discussion
Sputtered yttrium coins are an alternative and feasible route for the production of 89Zr with high
89Zr

recovery and easy processing. The difference in the activity measured on sputtered coins to

the theoretical yields may be due to error in the thickness used in the theoretical calculations.
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The thickness of the sputtered coins was determined using the mass of the yttrium sputtered onto
the niobium coin and likely, the yttrium is not at 100% theoretical density. We found that the
sputtered coins with a 0.75 mm aluminum degrader bombarded with a beam energy of 17.8 MeV
giving a transmitted energy of 12.8 MeV on the sputtered coins and a current of 40 μA for 2
hours produced the best results. No 88Zr was observed in the analysis of the sputtered coins due
to the degradation of the beam, providing 100% radionuclidic purity similar to the reports from
low energy beam production of 89Zr in literature [24]. The majority of activity for the sputtered
coins were recovered in 1 mL (2 aliquots) of 1 M oxalic acid which was comparable to Holland
et al. who reported >99% recovery in 3 mL [3]. We were able to obtain a specific activity of 108
± 7 mCi/µmol which is somewhat lower than Holland et al. (470-1195 mCi/μmol) [3], however
this may be due to the lower amounts of activity produced during our scale up phase. ICP-MS
analysis of the yttrium coin and the sputtered coins showed 99.99% yttrium removed with 178
μg of yttrium in the final solution and 99.93-100% of yttrium was removed with 0-42 μg of
yttrium in the final solution, respectively. Furthermore, the ICP-MS analysis showed a higher
concentration of zirconium in the production from the solid yttrium coins contributing to the
lower specific activity obtained when using this method. The sputtered coins showed higher
concentrations of aluminum and iron than the yttrium coin. Further investigations for these
trends are ongoing. DFO-trastuzumab was successful labeled with the purified activity from the
sputtered coins giving yields of 98-100% with a concentration of 13.1 mCi/mL of buffered and
pH adjusted

89Zr.

This is consistent with other reported labeling yields. Marquez et al. reported

>95% yield with pertuzumab and Holland et al. reported >70% yielding with DFO-trastuzumab
[2, 21].
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In the future, longer irradiations of sputtered coins with higher currents will be performed using a
0.75 mm aluminum degrader and 17.8 MeV incident beam energy and a transmission energy of
12.8 MeV. Separation methods to optimize specific activity will be investigated as well as
automated processes for the purification and recovery of 89Zr.

2.5 Conclusions
The use of sputtered yttrium on niobium coins have shown to be an effective and alternative
means of production of 89Zr. The degradation of the proton beam via aluminum degrader to <13
MeV eliminated the production of 88Zr and allowed for 100% radionuclidic purity. The integrity
of the sputtered coins was not compromised, unlike that of the yttrium coins at higher current
and longer irradiation periods. The sputtered coins resulted in more control over yttrium mass
and the target cross sectional area. This allowed for an efficient separation of 89Zr from the target
material and a dissolution time that is significantly shorter than the yttrium coins that resulted in
a product with higher specific activity.
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Chapter 3
Radiochemical separation of 89Zr from
yttrium utilizing an inorganic ion-exchanger
[This work has been presented previously at the 255th ACS National Meeting as “Inorganic ionexchangers for radiochemical separations of Y/Zr and Ti/Sc,” Stacy L Queern, Cienna L.
Manderbach, Cathy S. Cutler, Dmitri G. Medvedev, Suzanne E. Lapi, and Jonathan M.
Fitzsimmons, March 2018]
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3.1 Introduction
Zirconium-89 (89Zr) is a positron emitter with a half-life of 78.4 hours and uses in medical
imaging applications. [1-3]. The long half-life of 89Zr can allow for imaging at longer time points
and matches well with the biological half-life of intact antibodies making it of high interest for
PET imaging [3-5]. The production of

89 Zr

is typically via irradiation of an yttrium (Y) target

which requires the removal of the Y before the

89Zr

can be used in radiolabeling. Current

separation of 89Zr from Y involves adsorption of 89Zr on hydroxamate or Zr resin (Triskem) after
dissolution of the target material in 2 M hydrochloric acid (HCl). The Y is eluted off the column
using 2 M HCl and then the column is washed with high purity water [1, 6-7]. The 89Zr is eluted
using heated 1 M oxalic acid [1, 6-7]. Although this is a relatively simple procedure for the
purification of

89Zr,

there are a few minor issues that can be improved upon. The heating of

oxalic acid can make it more difficult to implement this method into an automated system and
the oxalic acid is somewhat undesirable eluent as it needs to be removed before injection due to
toxicity issues [1, 8].
Crystalline silicotitanate (CST) is an inorganic exchange resin that has been used in the
purification of aqueous radioactive waste. In particular, the characteristics of poorly crystalline
silicotitanate (pCST) and highly crystalline silicotitanate (C-CST) have been reviewed mainly
for the waste removal of

137Cs.

pCST offers some advantageous adsorption properties over the

C-CST. Since pCST is heated less during formation, the particle size produced is smaller with
rough faces and edges [9-10]. These characteristics allow for an increased surface to volume
ratio to allow for more interactions but with less stable adsorption, thus increasing recovery of
the target isotope relative to C-CST [9-11]. pCST has shown to have strong stability to radiation
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and selectivity for cesium (Cs) and strontium (Sr) metals making it the preferred resin to separate
Cs and Sr from nuclear waste [9-10, 12]. In unpublished work conducted at Brookhaven National
Laboratory due to general interest in inorganic resins for radiation stability, pCST was found to
have a high affinity for Zr while having a low affinity for Y and thus is a promising support
material in the separation of Zr from Y.
Iminodiacetic acid (IDA) is a chelator that is currently being used in patients for hepatobiliary
(HIDA) scans [13]. IDA is a tridentate ligand (Figure 3-1), making it a weak chelator for

89Zr

which is tetravalent.

Figure 3-1 IDA chelation as a tridentate ligand

These characteristics allow for the potential use of IDA to remove

89Zr

from the pCST column

while maintaining a relatively unstable complex as not to interfere with subsequent labeling
chemistry. The aim of our work is to evaluate suitability of pCST for the separation of

89 Zr

using IDA as an eluant to allow for ease in automating the separation system and potentially
eliminating the need to remove the IDA chelator before injection.

3.2 Materials and Methods
Measurement of Distribution Coefficient: Kd studies for Zr and Y were carried out using pCST
resin. Stock solutions of 0.5 M ammonium acetate (NH4OAc) at pH 3 and 0.1 M iminodiacetic
acid (IDA) at pH 3 with 30 ppm Zr and 30 ppm Y were prepared. 30 mg of resin was weighed
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out into 15 mL falcon tubes. 5 mL of IDA was introduced to the resin with 100 L of metal
solution. The samples were placed on a shaker and allowed to reach equilibrium for at least 24
hours. 1.5 mL aliquots of the samples were taken and centrifuged to separate the resin from the
solution. 10 L of the supernatant was removed for ICP-MS analysis and diluted with 5 mL of
2% nitric acid. The Kd was calculated with the following equation where K d is binding affinity,
Ci is initial metal concentration, Ca is final metal concentration, Vx is total volume (mL), and Mx
is mass of resin (g).
Kd =

Ci −Ca
Ca

×

Vx

(1)

Mx

Data analysis was completed using Prism version 7 and p-values calculated using one-way
ANOVA multiple comparison with 95% confidence where p < 0.05 was considered significant.
89Zr

Purification with pCST : A 0.1 mL bed volume PEEK column was loaded with pCST resin

and conditioned with 10 mL of 0.5 M ammonium acetate at pH 3 at a flow rate of 0.1 mL/min. 2
mCi of crude

89 Zr

solution containing ~11 mg of Y in 2 M HCl obtained from the UAB

Cyclotron Facility was diluted to 2.5 mL using 0.5 M ammonium acetate at pH 3 and loaded
onto the column at a flow rate of 0.1 mL/min. The flow through of this loading was collected in
500 L fractions. The Y was then washed off the column using 0.5 M ammonium acetate at pH 3
at a flow rate of 0.1 mL/min in ten 500 L fractions (total volume of 5 mL).

89Zr

was eluted off

the column using 0.1 M IDA at pH 3 with a flow rate of 0.1 mL/min in twenty 500 L fractions
(total volume of 10 mL). 10 L aliquots of each fraction were removed and diluted with 2%
nitric acid for ICP-MS analysis of Y and Ti.
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89Zr

Labeling and Specific Activity: The antibody panitumumab, was purchased from Vectibix

(Thousand Oaks, CA), the chelator deferoxamine (DFO-SCN) was purchased from Macrocyclics
(Plano, TX) and all other reagents were purchased through Fisher Scientific. For test labeling
studies with

89Zr,

panitumumab was conjugated with DFO-SCN using a 10:1 molar ratio of

antibody to chelator where 15 L of 20 mg/mL DFO-SCN, 150 L of 8 mg/mL panitumumab
and 135 L of 0.1 sodium carbonate buffer pH 9 were allowed to react for 1 h on a thermoshaker
set for 37C at 350 rpm [14]. The final product was purified on a Zeba spin desalting column (40
kDa molecular weight cutoff). The labeling was carried out using 12.5 L of 1 mg/mL DFOpanitumumab which was aliquoted into a microcentrifuge for each labeling.

89Zr-IDA

was

neutralized using 1 M HEPES. A ~6 L aliquot (5-7 µCi) was added to each of the
corresponding labeling microcentrifuge tubes. For comparison to the standard method,

89 Zr-

oxalate, produced in house, was neutralized using 1 M HEPES and 2 M NaOH [6]. 50 Ci (~6
L) of the neutralized standard

89Zr

was added to each of the corresponding labeling

microcentrifuge tubes. Then the microcentrifuge tubes were brought to 30 L in final volume
using 1 M HEPES (~11.5 L). The microcentrifuge tubes were placed on a thermoshaker set for
37C at 300 rpm for one hour and then challenged with 50 mM DTPA for 5 minutes. A 1 µL
aliquot of each labeling (both prior to the DTPA challenge and after) was spotted on iTLC-SG,
glass microfiber chromatography paper impregnated with silica gel (Agilent, CA) and developed
with 50 mM DTPA as mobile phase and analyzed on AR-2000 Radio-TLC imaging scanner
(Eckert & Ziegler, MA) to determine the labeling efficiency.
Effective specific activity (ESA) was determined using the DFO- titration method [1, 6]. A stock
solution of 5 mg/mL DFO in DMSO was serially diluted with 1 M HEPES. Each 200 L dilution
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had ~25 Ci (~30 L) of 89Zr-IDA added to each tube. The tubes were placed on a thermoshaker
set for 37C at 300 rpm for one hour and then challenged with 50 mM DTPA. A 1 µL aliquot of
each dilution was spotted on the iTLC-SG paper, developed with 50 mM DTPA as the mobile
phase, then analyzed on an AR-2000 Radio-TLC imaging scanner.

3.3 Results and Discussion
Distribution Coefficient Study: Ideally, for the distribution coefficient, K d, values, the difference
between the metals in the solvent should be large where the larger of the two values indicates the
ion has a stronger affinity for the resin under the conditions studied. This means the metal with
the lower Kd value will elute off in that solvent while the metal with the larger K d value will be
retained on the resin. These ideal conditions can be seen in Figure 3-2 for 0.5 M ammonium
acetate pH 3 where the Kd value for Zr was 7700500 mL/g and the Kd value for Y was 59090
mL/g. The Kd values for the 0.1 M IDA pH 3 for Zr and Y were 73080 mL/g and 840110
mL/g, respectively. The large difference in the distribution coefficients between the Zr and Y for
the 0.5 M NH4OAc pH 3 shows that the Zr has a stronger affinity for the pCST resin and will be
retained on the resin while the Y is washed off. Although there is little difference between the K d
values for 0.1 M IDA pH 3, this shows that Zr has a low affinity for the resin under the
conditions studied. This data indicates the elution order should be 0.5 M ammonium acetate pH 3
to remove the Y and then 0.1 M IDA pH 3 to collect the Zr from the resin.
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Figure 3-2 Distribution coefficient study with 0.1 M NH4OAc (pH 3) and 0.1 M IDA (pH 3)
89Zr

Separation with pCST: The activity elution profile shown in Figure 3-3 shows less than

63%

89Zr

breakthrough in the first 15 fractions (7.5 mL) and 8011% of

89Zr

was recovered

overall (10 mL) with 5816% in fraction 17 and 18 (1 mL). These small-scale separations
showed repeatable results with the majority of the activity being collected the second IDA
elution fraction.
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Figure 3-3 Activity elution profile illustrating average radioactivity per fraction

ICP-MS was used to investigate the amount of Y and Ti found in each fraction (Y being the
target material and Ti as part of the pCST crystalline structure). The Y and Ti elution profile are
provided in Figure 3-4. This figure shows that while both Y and Ti are present in the early
fractions, they are no longer eluted after fraction 8. The Ti analysis shows that any loose metal or
resin has been removed before the collection of the 89Zr in fractions 17 and 18.
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Figure 3-4 ICP-MS percent by mass elution profile for Y and Ti for each fraction
89Zr

Labeling and Specific Activity: Labeling studies performed using DFO-panitumumab

showed 978% labeling for

89Zr-IDA

and 99.80.6%

labeling reaction was challenged with DTPA, the
labeling remain and the

89Zr-oxalate

89Zr-oxalate

89 Zr-IDA

(p = 0.2381). When the

method labeled antibody had 948%

method labeled antibody had 966% remain (p = 0.3885).

The 89Zr-IDA compared to 89Zr-oxalate show no significant difference between the labeling even
when challenged with DTPA. This shows that this alternative method results in a high-quality
product suitable for radiolabeling studies. Using the standard method to determine the ESA of
89

Zr-IDA resulted in an ESA of 243 mCi/mol. The relatively low ESA can be attributed to the

small batches of activity studied thus far. ESA values in literature typically range from 1087
mCi/mol reported by Queern et al. to 470-1195 mCi/mol reported by Holland et al. [1, 6]. It is
likely that scaling up the batch size of activity will result in a higher ESA.
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3.4 Conclusions
Herein, we evaluated the low-level activity separations of 89Zr from Y to evaluate the suitability
of pCST resin using an IDA eluant as a new purification strategy. This method may provide ease
in automating the separation system and potentially eliminates the need to remove the oxalate
chelator before injection. Our work shows reproducible results in these low-level separations.
The test labeling of antibodies with the recovered

89Zr

showed that DFO conjugated antibodies

can be successfully labeled with comparable yields to current methods. Overall, this method
shows potential for an alternative method for the separation of 89Zr from Y.
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Chapter 4
Radiolabeled nano-hydroxyapatite as a
new platform for PET imaging agents
[This work has been submitted previously as “Radiolabeled nano-hydroxyapatite as a new
platform for PET imaging agents,” Stacy L Queern, Tolulope A. Aweda, Nicholas A. Clanton,
Alan R. Ketring, Heather M. Hennkens, and Suzanne E. Lapi, Molecular Imaging. 2018]
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4.1 Introduction
There is a large breadth of uses for nanoparticles, such as targeted drug delivery, photoablation
therapy and bioimaging [1-2]. The use of nanoparticles in the medical field has growing interest
due to their many advantageous characteristics, including availability in many shapes, sizes and
with varying surface characteristics [3-4]. Nanoparticles offer a large surface to volume ratio that
makes them potential candidates for targeted molecular imaging and therapy [5].
Zirconium-89 (89Zr) is commonly used in the research arena for positron emission tomography
(PET) imaging of radiolabeled monoclonal antibodies. This is in part due to its long half-life
(78.4 h), which is compatible with the biological half-lives of antibodies and nanoparticles [6-8].
It is well known that free 89Zr is a bone seeker, which means that if the

89 Zr

decomplexes from

the chelating agent, it will accumulate in the bone, [7, 9]. There are several radionuclides that are
considered bone seekers due to their high affinity for bone, including fluorine-18 (18F),
samarium-153 (153Sm), and

89 Zr.

These bone seekers have great potential for PET imaging or

cancer therapy, but if they are not stably complexed or otherwise attached to the targeting vector
in vivo, they may accumulate in the bone [9]. Although bone uptake of

89Zr

is not commonly

seen in human subjects, it remains a problem in preclinical studies and may cause difficulty in
translating dosimetry from animal models to humans [7].
Bone is made of a matrix of compounds, the main component of which is hydroxyapatite (HAp),
(HCa5O13P3) [10-12]. Current uses of HAp in the dental and medical fields include dental enamel
replacement, bone grafting and drug delivery [13-15]. Although HAp is well known, little work
has been done with nano-hydroxyapatite (nHAp) as a radiolabeled PET tracer. In one study,
Zheng et al. successfully labeled nHAp with
48

18F

to determine biodistribution and

pharmacokinetics of

18F-nHAp

using PET imaging and showed that

18F-nHAp

was retained in

the body for at least 160 minutes [16]. The long circulation period of nHAp means that longerlived radionuclides are required for the development of nHAp-based tumor targeting agents.
The goal of our research is to exploit the natural affinity of 89Zr and other radionuclides for bone
to synthesize radiolabeled nHAp particles. Development of rapid radiochemistry could enable a
new class of imaging agents with kit-like formulations. The use of nHAp provides substantial
surface area for radiolabeling and the potential for attachment of targeting moieties and drug
loading. We investigated labeling efficiencies of several radionuclides for nHAp and the stability
of the radiolabeled products over two half-lives. Analyses and comparisons of the size and shape
of nHAp and the role of these parameters on labeling, stability and biodistribution in mice were
assessed.

4.2 Methods
Materials
89Zr, 18F,

and 55Co were produced by the University of Alabama at Birmingham (UAB) cyclotron

facility (Birmingham, AL) [17-18],

64Cu

was purchased from Washington University School of

Medicine (WUSM) cyclotron facility (St. Louis, MO) and

153Sm

was obtained from the

University of Missouri Research Reactor (MURR) (Columbia, MO). Sphere-shaped HAp
nanopowder with a reported particle size of <200 nm was purchased from Sigma Aldrich (St.
Louis, MO). Needle-shaped HAp particles with a reported average particle length of 20 nm were
purchased from M K Impex Corp. (Mississauga, Ontario, Canada). All other chemicals were
purchased from Fisher Scientific.
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Particle Characterization
Transmission Electron Microscopy (TEM) was performed at either Washington University in St.
Louis (WUSTL) Nano Research Facility with a FEI Tecnai G 2 Spirit or at UAB High Resolution
Imaging Facility with a FEI Tecnai T12 Spirit. All samples were suspended in methanol and
placed on a carbon support film with 200 mesh copper.

Radiolabeling and Stability Studies
All labeling studies were conducted with 50 µg of nHAp, either sphere-shaped or needle-shaped,
dispersed in 300 µL of 1x PBS. The pH of all radioisotope solutions was adjusted to 7.1 using 1
M HEPES (pH=7.1) as a buffer and 2 M NaOH and/or 1 M HCl for pH adjustments. A 50 Ci (1
– 110 L) aliquot of the radionuclide solution was added to the nHAp solution and then
incubated at 37 ͦ C with agitation for several time points up to 60 minutes. The samples were
centrifuged at 15,000 rpm for 2 minutes and the supernatant was removed. The samples were
washed three times with 1 mL of 1x PBS, centrifuged, supernatant removed, and the
radioactivity associated with the nHAp was measured with a CRC-25 dose calibrator (Capintec,
Inc., NJ). Determination of the maximum amount of radioactivity adhered to the nHAp was
investigated using variable activity (40 – 200 Ci) added to the 50 µg of nHAp mass. Tenminute labeling intervals were studied. 64Cu-nHAp and 55Co-nHAp were used as controls, since
these isotopes are not bone seekers.
All stability studies were completed using the highest achieved specific activity radiolabeled
nHAp over the course of two half-lives of the radioisotope in 300 µL of either fetal bovine serum
(FBS) or human serum (HS). The 64Cu-nHAp and 55Co-nHAp were used as controls for the FBS
studies, and 64Cu-nHAp was used as a control for the HS study. In order to determine the amount
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of radioactivity still associated with the particles, the particles were centrifuged after two halflives at 15,000 rpm for 2 minutes, the serum was removed, and the activity associated with the
pellet was measured.

Biodistribution Studies
All animal studies were conducted under a protocol approved by the Institutional Animal Care
and Use Committee (IACUC) at the University of Alabama at Birmingham. Biodistribution
studies were carried out for both nHAp morphologies in normal mice (32-38 days old, male, CD1 IGS, n=4). 50 µCi of 89Zr-nHAp in 100 µL of 0.9% sodium chloride solution was injected via
tail vein. Animals were sacrificed via cervical dislocation at 4 hours, 24 hours, 72 hours and 7
days post injection, and organs were harvested and analyzed for radioactivity using a 2480
Wizard 2 Gamma Counter (Perkin Elmer, MA). Radioactivity associated with each organ is
expressed as percentage of injected dose per gram of organ (%ID/g).

Statistical Analysis
All data is reported as mean  standard deviation and was calculated using Microsoft Excel
version 16. All p-values were determined using Prism version 7 one-way ANOVA multiple
comparison with 95% confidence where p < 0.05 was considered significant.

4.3 Results
Particle Characterization
TEM of the two types of nHAp confirmed the morphology of each and allowed determination of
average particle size. Figure 4-1 shows an image for each of the morphologies. Both
morphologies illustrated extremely variable particle sizes. By TEM, the sphere-shaped nHAps
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were found to have a range of 13 nm – 1149 nm, with an average particle diameter size of 206
nm (n=109). The needle-shaped nHAp ranged in length from 9 nm – 357 nm, with an average
length of 76 nm (n=76) and ranged in width from 6 nm – 51 nm, with an average width of 19 nm
(n=53).

Figure 4-1 TEM images of sphere-shaped particles (A) and needle-shaped particles (B) Radiolabeling and Stability
Studies

nHAp was radiolabeled with 89Zr, 18F, 153Sm, 64Cu, and 55Co and the stability of the adhesion of
each radionuclide to nHAp was assessed. The time needed to incorporate maximum radioactivity
on the nHAp, maximum specific activity achievable, and stability in FBS and HS for two halflives were determined for each radionuclide-nHAp. A summary of this data is shown in Table 41.
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Table 4-1 Labeling and Stability of Radiolabeled Sphere- vs. Needle-Shaped nHAp

Half-life
Radionuclide
(h)

Minimal
Time for
Maximum

Maximum

% Intact
After

% Intact
After

Specific Activity

Two

Two

(µCi/µg)

Half-lives

Half-lives

(FBS)†

(HS)†

Sphere: 1.31±0.19

100±3

91±2

Needle: 2.8±0.3

98.2±1.2

92±2

Sphere: 27±3

86.9±1.3

Labeling
(min)

89Zr

18F

153Sm

64Cu

55Co

78.41

1.83

46.28

12.70

17.53

10

NP*

5
Needle: 38.4±0.2

75.5±1.6

Sphere: 11.75±0.18

91.4±1.1
NP*

10
Needle: 11.0±0.3

90.4±1.1

Sphere: 12.41±0.02

64±2

56±3

Needle: 14.27±0.13

23.74±0.10

35±2

Sphere: 0.76±0.09

55±5

15

NP*

30
Needle: 1.49±0.11

†n=3; *NP

44±3

- not performed

Figure 4-2 shows the radiolabeling yields at various labeling times for the radionuclides studied.
Over 90% labeling was achieved for all bone seeking radionuclides in less than 10 minutes, with
relatively low radiolabeling yields achieved for the non-bone seeker, 55Co, as expected.
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Figure 4-2 Radiolabeling trends of nHAp for radionuclides studied

Tables 4-1 and 4-2 show the significant difference between the stabilities of the sphere- and
needle-shaped particles after two half-lives, where the radiolabeled sphere-shaped particles were
more stable than the needle-shaped particles. Furthermore, the data shows that the stability trend
for both morphologies was

89Zr

>

153Sm

>

18F

> 64Cu >

55Co. 89Zr-nHAp

and

64Cu-nHAp

were

further tested for stability in HS for two half-lives. The data in Table 4-1 shows, as expected, the
89Zr

radiolabeled sphere-shaped and needle-shaped particles are stable in HS, while the

particles are less stable. The 89Zr particles have similar stability in both HS and FBS.
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64Cu

Table 4-2 Statistical Data (p-values) for the Stability of the Labeled nHAp in FBS

sphere
needle

18F

153Sm

64Cu

55Co

89Zr

>0.9999 <0.0001

0.0058

<0.0001 <0.0001

18F

<0.0001 <0.0001

0.0188

<0.0001 <0.0001

153

Sm

*Black

89Zr

0.0008

<0.0001 >0.9999 <0.0001 <0.0001

64Cu

<0.0001 <0.0001 <0.0001 <0.0001

55Co

<0.0001 <0.0001 <0.0001 <0.0001 <0.0001

0.0005

font represents p-values of sphere-shaped particles relative to other sphere-shaped

particles, red font represents p-values of needle-shaped particles relative to other needle-shaped
particles, and blue font represents p-values of sphere-shaped particles relative to needle-shaped
particles for the same radionuclide.
The biodistributions in normal mice for both 89Zr-nHAp morphologies are shown in Figure 4-3.
These data show less than 5% bone uptake, with uptake in the lung and retention in the liver and
spleen (likely due to particle size). The needle-shaped nHAp had less uptake in the bone (p <
0.003), lungs (p < 0.01) and kidneys (p < 0.001) compared to the sphere-shaped nHAp at seven
days. The biodistribution shows the smaller particles (needle-shaped) have less uptake in bone,
kidney and lung, which implies that smaller particles may make better tumor targeting agents [3].
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Figure 4-3 (A) Biodistribution for sphere-shaped 89Zr-nHAp and (B) biodistribution for needle-shaped 89Zr-nHAp
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4.4 Discussion
The goal of our research was to exploit the natural affinity of

89 Zr

and other radionuclides for

bone to develop a rapid labeling technique for nHAp. In order to evaluate the potential of nHAp
as a new class of imaging agents, we examined the labeling efficiencies and stability of
adsorption to nHAp for several radionuclides. The role of the size and shape of nHAp on
labeling and stability for 89Zr, 18F, 153Sm, 64Cu and 55Co was investigated. The two different 89ZrnHAp morphologies were used for biodistribution studies in normal mice.
The TEM data showed the morphology and size of both the commercially obtained sphere- and
needle-shaped nHAp. Both the sphere- and needle-shaped particles have a large variability from
the reported average particle size. The sphere-shaped particles show greater deviation in particle
size, and Figure 4-1A clearly shows that the size of these nHAp particles is not uniform. The
needle-shaped particles are significantly larger than the reported value but are smaller relative to
the sphere-shaped nHAp.
The labeling data show that radiolabeling of nHAp with

18F

proceeded rapidly (5 minutes),

which is consistent with literature data [16]. Higher specific activity was achieved with the
needle-shaped nHAp for all radionuclides except

153Sm,

for which the specific activities were

approximately the same. This is expected due to the increased surface to volume ratio for smaller
particles. The stability data show that (as expected) particles radiolabeled with known bone
seekers have higher stability than the non-bone seekers, where 89Zr and 153Sm exhibited the best
stability with > 98.2% and > 90.4% intact after two half-lives (156.8 h and 92.6 h), respectively,
for both nHAp morphologies. It is possible that
153Sm

18F

showed less stability compared to

because it is a non-metal with a negative charge (F-) compared to
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89Zr4+

and

89Zr

and

153Sm3+,

which are transition metals with positive charges. This positive charge may offer additional
stability due to ionic interactions between the metals and the negatively-charged hydroxide (OH-)
groups on the surface of the nanoparticles. However, the

18F

can only adhere via covalent or

hydrogen bonding, both of which are weaker than ionic bonding. For

18F, 64Cu,

and

55Co,

the

radiolabeled needle-shaped nHAp showed lower stability than the sphere-shaped nHAp with pvalues less than 0.01. This was further confirmed in the 64Cu-nHAP stability experiments using
human serum. Sphere- and needle-shaped
and

55Co-nHAp

89Zr-nHAp

were equally stable, whereas

64Cu-nHAp

were less stable overall and the stabilities were less consistent between particle

morphologies. This trend for

64Cu-nHAp

and

55Co-nHAp

is expected, since they are not bone

seekers.
The biodistributions for both sphere-shaped and needle-shaped nHAp showed low 89Zr uptake in
the bone (<5% ID/g), with localization in the lungs, liver and spleen. In comparison, Marquez et
al. reported biodistributions with upwards of 20% ID/g uptake in the bone with

89Zr-DFO-

pertuzumab, a monoclonal antibody that targets HER2 receptors [19]. The bone uptake can be
attributed to the likely decomplexation of the

89 Zr

from the

89 Zr-DFO.

Our work clearly

demonstrates significantly less uptake in the bone, which supports low desorption of the
from

89Zr-nHAp

89 Zr

in vivo. Overall, the data show that this strategy has potential for the

development of imaging and therapy agents with bone seeking radionuclides using nHAp.

4.5 Conclusions
Our studies illustrate how the high affinity of 89Zr for nHAp may aid in the development of new
imaging agents. Overall,

89

Zr-nHAp was shown to be a good candidate for the development of

new targeted PET imaging agents. The particles are easily labeled with bone seeking
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radionuclides and have high in vitro stability with little bone uptake in vivo. Our future work will
include the modification of nHAp to include tumor targeting agents and the assessment of the
effect these modifications have on labeling, in vitro stability and in vivo pharmacokinetics.
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Chapter 5
89

Zr-nano-hydroxyapatite modified with
phospha-TOC as a targeted PET agent

[This work has been presented previously at the ISRS 2017 meeting as “89Zrnanohydroxyapatite-phospha-TOC as a new PET imaging agent” Stacy L Queern, Adriana V. F.
Massicano, Jennifer L. Burkemper, Nicholas A. Clanton, and Suzanne E. Lapi, May 2018]
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5.1 Introduction
Nanoparticles are used in drug delivery and therapy in the medical field because they offer
unique properties due their size and surface characteristics [1-2]. Currently there are many types
of nanoparticles being used in biomedical research as the variety in the morphology results in an
expansive research toolbox. For example, the large surface to volume ratio of nanoparticles
provides a platform for targeted imaging and/or therapy [3].
Zirconium-89 (89Zr) has a half-life of 3.27 days which is compatible with the biological half-life
of antibodies and nanoparticles [4-6]. This characteristic has made this radionuclide of
significant interest in the molecular imaging field. An additional important feature to note is that
free 89Zr is a bone seeker. This means that 89Zr has a high affinity for bone, thus if decomplexes
from the compound it will accumulate in the bone [7-8]. Although this is not frequently seen in
human studies, it may cause issues with preclinical experiments and translation of dosimetry to
clinical trials [5, 7].
One way to label nanoparticles with

89Zr

was been discussed in our previous work (Chapter 4)

using nanohydroxyapatite (nHAp). nHAp is the main component in the bone matrix [9-11] and
thus

89Zr

has a natural high affinity for nHAp. Our previous studies have shown rapid labeling

and high in vitro stability with minimum release and bone uptake in vivo. Modification of nHAp
would allow for targeted molecular imaging or therapy. As a proof of concept, the peptide,
[Tyr3]octreotide (TOC) was used to modify nHAp in order target somatostatin receptors, namely
SSTR2 receptors, which are over-expressed on neuroendocrine tumors [12-14]
The aim of this work was to perform a rapid modification of nHAp using an analog of TOC to
target neuroendocrine tumors. Herein, we discuss the preparation of co-precipitated
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89Zr

with

nHAp and the modification of the nHAp with phospha-TOC. The binding of the modified

89 Zr-

nHAp to rat pancreatic tumor cells, AR42J, that overexpress SSTR2 and distribution in
immunodeficient mice with tumor xenografts from the same cell line were examined to
investigate specific targeting of the modified nHAp.

5.2 Methods
Materials
89Zr

was produced by the Cyclotron Facility at University of Alabama at Birmingham [4].

[Tyr3]-octreotide (TOC) was obtained from CPC Scientific (Sunnyvale, CA) and phospha-TOC
({d-PHE}CY{d-TRP}KTC{pTHR}), an analog of TOC, was obtained from GenScript
(Piscataway, NJ). All other chemical reagents and supplies were purchased from Fisher
Scientific (Pittsburgh,PA) or Sigma (St. Louis, MO).

Co-precipitation preparation of 89Zr-nHAp
A solution of 2.5 ml of 0.5 M calcium chloride (CaCl2), 2.5 ml of 0.1 M trisodium citrate
(Na3C6H5O7) and approximately 100 L of 89Zr were mixed and allowed to react for 30 minutes
on a vortexer. A second solution of 1.25 mL 0.03 M ammonium hydrogen phosphate
((NH4)2HPO4) and 0.5 mL of ammonium hydroxide (NH 4OH) was added dropwise to the first
solution then pH adjusted to pH 9 using concentrated nitric acid. The reaction was allowed to
proceed for another 30 minutes before the final product was removed via centrifugation and
washed three times with 18Ω milli-Q water removing water with centrifugation each time [15].
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Transmission Electron Microscopy (TEM) was performed to characterize the nHAp at UAB
High Resolution Imaging Facility with a FEI Tecnai T12 Spirit. All samples were suspended in
methanol and a 1 μL aliquot was spotted on a carbon support film with 200 mesh copper.
Stability studies were completed using approximately 200 µCi of co-precipitated 89Zr-nHAp over
the course of 7 d in 300 µL of fetal bovine serum (FBS). After incubation, the particles were
centrifuged at 15,000 rpm for 2 minutes, the serum was removed, and the activity associated with
the pellet was measured on a Capintec CRC-25 dose calibrator (Florham Park, NJ).

Modification of 89Zr-nHAp with phospha-TOC
For modification of 89Zr-nHAp, 2 mg of phospha-TOC was dissolved in water and introduced to
the reaction vessel with ~300 μg (~1 mCi) of 89Zr-nHAp. The reaction was allowed to proceed
for one hour at room temperature on a thermoshaker. The proposed reaction mechanism is given
in Figure 5-1. The product was removed using centrifugation and washed several times with
PBS. Once the

89Zr

had decayed ten half-lives, the washes and final product were analyzed on

Agilent 6530 Quadrupole Time-of-Flight (QTOF) LC/MS (Santa Clara, CA). A 500 μL aliquot
of each wash was analyzed without any further dilutions. The final product was dissolved in 100
μL chloroform and a 10 μL sample was diluted to 500 μL of 50% acetonitrile with 0.1% formic
acid and then analyzed on the QTOF.
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Figure 5-1 Modification of nHAp with phospha-TOC

Cell Studies with 89Zr-nHAp-phosph-TOC
The specific targeting of 89Zr-nHAp-phospha-TOC was tested on AR42J cell lines which have an
overexpression of somatostatin receptor 2 (SSTR2) [13,16]. Approximately 2 x 106 million of
cells were plated per well on 12-well plates. 0.5 μCi (1.3 μg)

89Zr-nHAp-phospha-TOC

was

introduced to all wells where 4 of the wells were designated for each of the following: nonblocking, blocking and bare nanoparticles (no peptide). The blocking study used ~380 μg TOC
to block the SSTR2 receptors to show that specific binding was occurring. The cells were
incubated at 37ᴼC in a 5% CO2 atmosphere for 2 hours. The cells were washed with cold PBS
two times and then trypsinized for 5 minutes. The trypsin was neutralized with an equivalent
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volume of cell media and then the cells were collected. The collected cells and each wash were
analyzed for radioactivity using a 2480 Wizard 2 Gamma Counter (Perkin Elmer, MA).
Cells were counted directly after gamma analysis. A 20 µL aliquot of the cell sample was placed
on a plastic cell counting chamber and counted in a Nexcelom Cellometer Auto T4 (Lawrence,
MA) using Cellometer Auto Center version 3.3.7.1. Bovine serum albumin (BSA) protein assay
was completed following the cell counts. BSA calibration standards for the protein bioassay were
of 2000, 1000, 500, 250, 125, 62.5, 31.25, and 0 µg/mL in concentration. All samples had a 5fold dilution in the same matrix. 10 µL of each standard and sample was aliquoted in triplicate
into a 96-well plate.100 µL of bicinchoninic acid color agent was added to each well and
incubated for 30 minutes at 37ᴼC. The plate was analyzed on BioTek Synergy Mx plate reader
(Winooski, VT) using Gen5 All-in-One version 2.09 software.

Animal Studies with 89Zr-nHAp-phospha-TOC
All animal studies were conducted under a protocol approved by the Institutional Animal Care
and Use Committee (IACUC) at the University of Alabama at Birmingham. Seven-week-old
female athymic nude mice were anesthetized and implanted with approximately 3 x 10 6 AR42J
rat pancreatic tumor cells on their right hind quarters. The tumor was allowed to grow for 10-14
days before imaging and biodistribution studies were performed.
Each mouse was injected with approximately 100 μCi (~200 μg) of 89Zr-nHAp-phospha-TOC in
100 μL of 0.9% sodium chloride solution via tail vein. PET imaging was conducted using a Sofie
BioSciences GNEXT PET/CT scanner (Dulles, VA) at 4, 24, and 72 h post-injection with postimaging biodistributions to examine the uptake of

89

Zr-nHAp-phospha-TOC over time. To

determine if specific uptake was occurring, a blocking study was performed using TOC to block
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the SSTR2 receptors on the tumors. The blocking PET imaging study was completed at 24 h
post-injection with post-imaging biodistributions using 100 µg of TOC co-injected with the 100
µCi of 89Zr-nHAp-phospha-TOC in 100 µL of 0.9% sodium chloride solution via tail vein [13].
All images were analyzed using Invicro VivoQuant version 3.5 software (Boston, MA).
For the post-imaging biodistribution studies, the mice were sacrificed via cervical dislocation at
4, 24, 72 hours post-injection, and organs were harvested and analyzed for radioactivity using a
2480 Wizard 2 Gamma Counter (Perkin Elmer, MA). Radioactivity associated with each organ
is expressed as percentage of injected dose per gram of organ (%ID/g).

Statistical Analysis
Prism version 7 was used to determine the p-values using one-way ANOVA multiple
comparison with 95% confidence where p < 0.05 was considered significant.

5.3 Results and Discussion
Co-precipitation preparation of 89Zr-nHAp
The production of the co-precipitated

89Zr-nHAp

resulted in a 98.7±1.3% radiochemical yield

which illustrates that the coprecipitation labeling is highly efficient. Figure 5-2 shows an image
of the co-precipitated

89 Zr-nHAp.

The TEM image showed irregular spherical particle shapes

that measure an average of 64.8 nm (n=108) with a range in particle size of 8.9 – 175 nm. The
average particle size and range of the co-precipitated

89Zr-nHAp

compared to the needle- and

sphere-shaped particles showed smaller average particle sizes as well as a narrower range.
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Figure 5-2 TEM image of co-precipitated 89Zr-nHAp

The stability of the co-precipitated 89Zr-nHAp over the course of 7 days (~ 2 half-lives) showed
that 96 ± 3% of the radioactivity remained associated with the particles. This stability showed no
significant difference compared to the previous work where the

89Zr

labeled sphere-shaped

particles were 100 ± 3% (p = 0.105) and 89Zr labeled needle-shaped particles were 98.2 ± 1.2%
(p = 0.425) intact after two half-lives. The particle size in conjunction with the stability results
led to the decision to use the co-precipitated

89 Zr-nHAp

particles for further experiments

involving the modification of the nanoparticle for receptor targeting.

Modification of 89Zr-nHAp with phospha-TOC
The QTOF calibration curve for phospha-TOC and washes for the modified

89Zr-nHAp-

phospha-TOC are provided in Figure 5-3. The QTOF data showed that there was no phosphaTOC present after the fifth wash therefore validating that the mass peak at 1129 on the final
product is the phospha-TOC attached to the

89Zr-nHAp.

attached to the nHAp was 1.019 µmol/mg of nHAp.
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The final amount of the phospha-TOC

Figure 5-3 Phospha-TOC concentration calibration curve (left)
and the phospha-TOC measurement for each wash (right)

Cell Studies with 89Zr-nHAp-phosph-TOC
Figure 5-4 shows the percent binding of the

89 Zr-nHAp-phospha-TOC

per µg of protein where

non-blocking had 0.012 ± 0.002 %/µg, blocking had 0.0088 ± 0.0013 %/µg and bare particles
had 0.0013 ± 0.0002 %/µg, and the percent binding of the 89Zr-nHAp-phospha-TOC per million
cells where non-blocking yielded 2.3 ± 0.7 % per million cells, blocking yielded 1.5 ± 0.3 % per
million cells and bare particles yielded 0.18 ± 0.03 % per million cells. In both graphs, the data
show there is significant difference between the non-blocked cells and the blocked cell for both
per µg of protein (p= 0.0006) and for the percent binding per million of cells (p=0.0007). This is
also true of the comparison between the non-blocked cells targeted with

89

Zr-nHAp-phospha-

TOC and the cells that were targeted with bare particles (no peptide), where the p-value for the
percent binding per µg of protein was 0.0009 and for the percent binding per millions of cells
was 0.0006. This study shows that the bare particles have minimal nonspecific binding and the
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success of the nHAp modification for targeting the SSTR2 receptors. These cell studies confirm
that the 89Zr-nHAp is modified with phospha-TOC and illustrates specific targeting.

Figure 5-4 Cell Study using AR42J cell which overexpress SSTR2 receptors

Animal Studies with 89Zr-nHAp-phospha-TOC
PET imaging studies for the non-blocking mice at 4, 24, and 72 hours with the post-imaging
biodistribution data can be found in figure 5-5. The images show tumor uptake at each time
point. The standard uptake value (SUV) data shown in Table 5-1 shows the highest SUV at 24
hours where the SUV for 4 h, 24 h and 72 h was 0.34 ± 0.19, 0.9 ± 0.5, and 0.6 ± 0.2,
respectively, although there is no significant difference between the three points (p=0.1073).
Furthermore, in Table 5-1, there is no significant difference in SUV between the tumor and the
background (muscle) at 4 h. However, a significant difference was found between the tumor and
the background (muscle) during the 24-hour and 72-hour time periods with p-values of 0.026 and
0.0055, respectively. The biodistribution shows no significant difference between tumor uptake
for each time point (p = 0.97) with background levels observed in the lungs, spleen, and liver.
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Figure 5-5 (A) PET imaging at 4, 24, and 72 hours of 89Zr-nHAp-phospha-TOC targeting agent for SSTR2 receptors
and (B) the corresponding post-imaging biodistribution
Table 5-1 SUV data for the different imaging time points for tumor and muscle

Time Point

SUV
for Tumor

SUV
for Muscle

Tumor to
Muscle
comparison
p-value

4 hours

0.34 ± 0.19

0.26 ± 0.08

0.24

24 hours

0.9 ± 0.5

0.24 ± 0.05

0.026

72 hours

0.6 ± 0.2

0.165 ± 0.017

0.0055

24 hours Blocked

0.16 ± 0.09

0.09 ± 0.02

0.079

Blocking studies were conducted with post imaging biodistribution conducted at 24 hours post
injection. Figure 5-6 displays the results of the blocking study compared to the non-blocking
study at the 24-hour time point. Image analysis illustrated a significant difference in the SUV
found in the non-blocked tumor relative to the blocked tumor at 24 h post injection. The SUV
value data for the non-blocked vs the blocked tumor was 0.9 ± 0.5 and 0.16 ± 0.09 with a p-value
of 0.018. In the biodistribution, significantly less uptake was found in the blocked tumor than
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the non-blocked tumor (p-value 0.042). For all other organs there was no significant difference in
uptake (p-values > 0.05). Overall, the blocking study illustrated specific targeting of the

89 Zr-

nHAp-phospha-TOC to the SSTR2 receptors in this tumor model.

Figure 5-6 PET imaging at 24 hours of 89Zr-nHAp-phospha-TOC for non-blocking versus block of SSTR2 receptors
using TOC and the corresponding post-imaging biodistribution

5.4 Conclusion
Our work shows that the co-precipitated 89Zr-nHAp had similar stability with better particle size
distribution compared to the commercially available nHAp in our previous work (Chapter 4).
The

89Zr-nHAp

was modified with phospha-TOC and the modified nHAp showed specific

targeting to SSTR2 on the AR42J cell line. The preliminary animal studies further confirm the
specific targeting between the non-blocked and blocked animal model. Overall, the preliminary
studies with 89Zr-nHAp-phospha-TOC are very promising for nHAp as a new platform for PET
imaging agents.
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Conclusions & Future Work
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6.1 Conclusions
Positron emission tomography (PET) imaging is a non-invasive and highly quantitative way to
diagnosis different diseases in several medical fields including oncology, neurology and
cardiology. The idea of personalized care using PET imaging is a key driver for advancing
research into developing new platforms for PET imaging agents leading to more effective
diagnosis and better treatment planning.

89Zr

has a long half-life, a low maximum positron

energy and established radiochemistry that has raised the demand for this isotope in nuclear
medicine. Although 89Zr has great potential as PET nuclide, it is a known bone seeker meaning if
it decomplexes it will be taken up in the bone. This bone uptake can be exploited by using the
natural affinity of 89Zr to create for nHAp based PET agents. Overall this work provides the basis
(proof of concept) for showing the implementation of nHAp as a new platform of PET imaging
agents.
89

Zr Production and Separation

Our initial studies aimed to produce 89Zr on the UAB TR-24 cyclotron. The proton beam energy
was degraded using an aluminum degrader to prevent the production of

88Zr

and an yttrium

sputtered target was designed to be compatible with the existing coin slot holder. The control
over the yttrium mass and the target cross section area allowed for an efficient separation of the
89

Zr from the yttrium with a final product with reasonable specific activity. This method is now

the standard practice for the production of 89Zr at UAB for human and research use.
An alternative method of separation for

89Zr

was investigated in collaboration with Brookhaven

National Laboratory, to allow for ease in automating the separation system and potentially
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eliminating the need to remove the chelator before injection. Low-level activity separations of
89Zr

from Y on pCST resin using IDA to elute off the

89Zr

showed reproducibility with

successful test labeling of a DFO conjugated antibody. These results show the potential for this
alternative method of separation.

Development of nHAp as PET Tracer
The natural affinity of

89Zr

and other radionuclides for bone was exploited to synthesize

radiolabeled nHAp particles and develop rapid radiochemistry to enable a new class of imaging
agents with kit-like formulations. The

89Zr-nHAp

was shown to be a good candidate for the

development of new targeted PET imaging agents while

153Sm-nHAp

was shown to be a strong

candidate for therapy. The particles were easily labeled with bone seeking radionuclides and
have high in vitro stability with little bone uptake in vivo.
A rapid modification method for nHAp using an analog of the peptide TOC to target SSTR2
receptors was developed using the preparation of co-precipitated 89Zr nHAp. The co-precipitated
89Zr-nHAp

had similar stability with better particle size distribution compared to the

commercially obtained sphere-shaped and needle-shaped nHAp. The

89Zr-nHAp

was rapidly

modified with phospha-TOC and the resulting agent showed specific targeting for the SSTR2
receptors. The preliminary animal studies further confirm the specific targeting between the nonblocked and blocked animal model. Overall, the preliminary studies with

89Zr-nHAp-phospha-

TOC are very promising for nHAp as a new platform for PET imaging agents.
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6.2 Future Work
89Zr

While the low-level activity separations with our new method of

purification were

promising, full size production scale separations should be performed. The production scale
separations will allow for comparisons of large batch specific activities and test labeling
comparisons. Further ICP-MS analysis should be conducted on the production scale separation
fractions for both Y and Ti. ICP-MS of the Ti will supply information on the stability of the resin
as more radioactivity is added to the column.
While the preliminary animal studies of the

89Zr-nHAp-phospha-TOC

were promising, further

studies should be conducted for reproducibility. Further investigations should be carried out to
determine if the bone uptake in the preliminary studies can be contributed to the

89Zr

decomplexing or nHAp adhering to the bone. Since nHAp is used in bone grafts, it might have
an affinity for damaged or growing bone. This may be investigated using aged normal mice that
have been tested negative for bone disease. There is also a huge potential for other studies using
the co-precipitation method to form nHAp as a multilabeled agent for theragnostic applications.
As example, multilabeling co-precipitated nHAp with

89Zr

and

153Sm

would allow for PET

imaging with the 89Zr while therapy is occurring using 153Sm.
In conclusion, the work present in this thesis has set up excellent groundwork for the
development of nHAp as a new platform for PET imaging agents. This work has shown the rapid
labeling and modification for the development of targeted agents is possible for nHAp. The
implementation of bone seeking radionuclides in the co-precipitation method of nHAp opens
new avenues of research for applications in imaging and targeted therapy.
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